News Release

BAXTER CONFIRMS ADVATE AVAILABILITY

DEERFIELD, Ill., October 9, 2003 - In response to unfounded rumors in the marketplace, Baxter Healthcare Corporation today stated that ADVATE, its Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method, (rAHF-PFM), continues to be available for sale in the United States and is not subject to any recall.

Baxter Healthcare Corporation is the principal U.S. operating subsidiary of Baxter International Inc. (NYSE: BAX). Baxter assists health-care professionals and their patients with treatment of complex medical conditions, including cancer, hemophilia, immune disorders, kidney disease and trauma. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives. For more information about Baxter, please visit www.baxter.com.

(Advate and Baxter are registered trademarks of Baxter International Inc. and its affiliates.)

FOR ADDITIONAL INFORMATION:

	Media Contacts: Deborah Spak, 847-948-2349 Investor Contacts: Neville Jeharajah, 847-948-2875 Mary Kay Ladone, 847-948-33